Saudi Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) posted a 4.2% year-on-year increase in net profit in the second quarter, reaching SAR 137.63 million ($36.70 million), compared to SAR 132.02 million in the same quarter last year.

On a half-year basis, the company's net profit for the first six months of 2026 rose 5.8% to SAR 305.84 million ($81.56 million), compared to SAR 289.06 million in the same period last year, bringing earnings per share to SAR 4.37 compared to SAR 0.13 for the same period last year, according to its preliminary financial results for the period ended June 30, 2026, published on the Saudi stock exchange (Tadawul).

On the revenue side, the company's sales in the second quarter grew 12.4% to SAR 445.31 million (approximately $118.75 million), compared to SAR 396.22 million in the corresponding quarter of 2025. First-half revenues also rose 8.5% to SAR 926.70 million (approximately $247.12 million).

Jamjoom Pharma attributed the revenue growth to higher sales volumes and the timely distribution of strategic commercial products, supported by continued strong demand in the Gulf, North Africa, and other export markets.

The company explained that net profit growth was supported by higher revenues and an expansion in gross profit margin, which partially offset the impact of increased operating expenses, promotional activities, commercial staffing costs, as well as the negative effect of foreign exchange rate fluctuations and a decline in income and profit share from a joint venture.

The board of directors of Jamjoom Pharma decided to distribute dividends of SAR 2.2 per share for the first half of this year.